Chuan-Hsu, Chen

Senior Marketing Director
TSH Biophparm Co., Ltd.

Chuan Hsu, Chen is Senior Marketing Director at TSH Biopharm, with responsibility for marketing, supply chain and agent management in Taiwan and oversea. Prior join TSH biopharma, he served in many different positions of commercial leadership in multinational/ local pharmaceutical companies in Taiwan. 

He managed various portfolios, include Oncology, Hematology, Ophthalmology, Cardiology, NGS and OTC fields for 20 years. With solid experienced in sales and marketing while excelling in new business and strategic plan development.

He was graduated from China Medical University and got pharmacist’s license in 1998. Then he took the master’s degree in traditional medicine in Yang Ming University in 2000. 
 

Speech title & Synopsis

Emerging Company of the Year

TSH Biopharm is a highly promising local pharmaceutical company established in 2010. In just over a decade, it has achieved remarkable success through extensive accumulation, innovative capabilities, product expansion, patent licensing, and overseas deployment. In the past six months, it has successfully acquired two companies, making it an undeniable rising star in the biotech industry.

TSH Biopharm places great emphasis on innovation, development, and sales, boasting a highly qualified team and establishing partnerships with numerous domestic and international institutions. Over the past four years, it has obtained three drug licenses in Taiwan and two overseas drug licenses, with the goal of securing two more domestic licenses this year. In the field of precision medicine, TSH Biopharm made a forward-looking move five years ago by launching an innovative, minimally invasive NGS liquid biopsy. This technology not only ensures accurate and reliable results but also offers high safety and convenience, significantly expanding the screening population and providing a basis for early diagnosis and recurrence monitoring for cancer patients.

In the future, TSH Biopharm will continue to address the unmet needs of patients, developing more innovative medical combinations, and constructing a more comprehensive medical product portfolio for the benefit of all humanity.